Log in or register to see all Alerts
New HTA Decisions in France
June 2020
Drug name
PREMINOR (amlodipine, ramipril)
Company
Leurquin Mediolanum
Decision date
23/10/2019
Therapeutic area
Cardiovascular conditions
Therapeutic sub area
Hypertension
Official notice date
07/11/2019
Reimbursement %
65
Decision (SMR)
Important
Decision (ASMR)
No improvement (V)
Indication
PREMINOR is indicated for the treatment of hypertension, in substitution therapy in well-controlled adults.
Decision Type
New technology assessment
Summary
The committee considered the actual benefit of PREMINOR to be 'important' in the indication of the Marketing Authorisation. It was concluded that PREMINOR does not provide any improvement in the medical service rendered (ASMR V). The committee proposed 65% reimbursement.